Bristol-Myers Squibb Company
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bristol-Myers Squibb Company's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $705 of operating cash. Higher than almost all Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 11.5 times. Higher than 95% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 94% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$705Over the last 3 years, every $100 of reported profit came with $705 of operating cash.
Higher than almost all Healthcare companies in United States.
Self-Funding Ratio
11.5×Over the last 3 years its own operating cash covered its investment spending (capex) 11.5 times.
Higher than 95% of Healthcare companies in United States.
Cash Locked Ratio
$24For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $24 tied up three years earlier.
More money tied up than 50% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +4% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+4% / -7%In 3 years sales changed by +4% while total assets changed by -7%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
6.3×Debt due within a year is covered 6.3 times by its yearly operating cash.
Higher than 81% of Healthcare companies in United States.
Cash Cushion Ratio
−29%Debt, after subtracting cash, equals 29% of its market value (net debt).
Lower than 88% of Healthcare companies in United States.
Tangible Assets Ratio
54%Of every $100 the company owns, $54 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 75% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 94% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bristol-Myers Squibb Company owes $0.75 for every $1 it owns. Bristol-Myers Squibb Company returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
13.5Investors pay $13.5 for every $1 of Bristol-Myers Squibb Company's yearly profit, lower than 77% of Healthcare companies in United States.
P/B ratio
5.63The share price is 5.63 times Bristol-Myers Squibb Company's book value per share, higher than 75% of Healthcare companies in United States.
Market cap
$125.6 BThe total market value of all of Bristol-Myers Squibb Company's shares at today's price (share price × number of shares), larger than 98% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$22.3 BWhat Bristol-Myers Squibb Company would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.93Net worth divided by the number of shares. The share price of $61.48 is 5.6 times this, which is the P/B above.
Return on equity (ROE)
46.6%Bristol-Myers Squibb Company earned 46.6% on its shareholders' money over the last year, higher than 97% of Healthcare companies in United States.
Owes vs Owns
0.75×Bristol-Myers Squibb Company owes $0.75 for every $1 it owns (moderate), higher than 74% of Healthcare companies in United States.
Dividend yield
4.00%Bristol-Myers Squibb Company pays 4.00% of its share price as dividends a year, higher than 94% of dividend-paying Healthcare companies in United States.
Revenue growth
-0%Revenue fell 0% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Profit growth
Back to profitBristol-Myers Squibb Company returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
14.6%Bristol-Myers Squibb Company keeps $15 of every $100 of revenue as net profit.
Cash quality
2.0×Cash from Bristol-Myers Squibb Company's business was 2.0× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
7.3×Bristol-Myers Squibb Company's operating profit covered its interest costs 7.3 times in the year to Dec 2025.
Cash vs debt
Net debtBristol-Myers Squibb Company had $36.5 B more debt than cash (net debt) at Dec 2025.
Questions
What is Bristol-Myers Squibb Company's P/E ratio?
Investors pay $13.5 for every $1 of Bristol-Myers Squibb Company's yearly profit, lower than 77% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bristol-Myers Squibb Company: $125.6 B ÷ $22.3 B (30 Jun 2026) = 5.6.
What is Bristol-Myers Squibb Company's return on equity?
Bristol-Myers Squibb Company earned 46.6% on its shareholders' money over the last year, higher than 97% of Healthcare companies in United States.
How much does Bristol-Myers Squibb Company owe compared with what it owns?
Bristol-Myers Squibb Company owes $0.75 for every $1 it owns (moderate), higher than 74% of Healthcare companies in United States.
Does Bristol-Myers Squibb Company pay a dividend?
Yes. Bristol-Myers Squibb Company pays 4.00% of its share price as dividends a year, higher than 94% of dividend-paying Healthcare companies in United States.
Is Bristol-Myers Squibb Company's revenue growing?
Revenue fell 0% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.